Multiple sclerosis associated with adalimumab: a case report and systematic review
A. A. Tappakhov,
T. Ya. Nikolaeva,
N. Yu. Gorokhova,
L. T. Okoneshnikova,
A. N. Ylakhova,
E. E. Konnikova https://doi.org/10.14412/2074-2711-2025-3-70-76
Abstract
Yakutsk 58, Belinskogo St., Yakutsk 677000, Russia; 4, Sergelyakhskoye Sh., Yakutsk 677010, Russia
The role of medications as risk factors for the development of multiple sclerosis (MS) remains controversial, although there is a limited number of studies addressing the influence of immunomodulatory drugs, contraceptives, and antibiotics on the onset of this disease. One group of medications associated with the development of demyelinating disorders (including MS) is tumor necrosis factor alpha (TNF-α) inhibitors. The limited number of reported cases of demyelination associated with this group of drugs (specifically, adalimumab), both in domestic and international medical practice, prompted the writing of this article. It presents a clinical case of a female patient who was prescribed adalimumab for the treatment of ankylosing spondylitis and developed MS in the fourth year of the disease (second year of therapy). In addition, a systematic review is presented including 13 patients described in the literature as well as our own case report.
About the Authors
A. A. Tappakhov
M.K. Ammosov North-Eastern Federal University
Russian Federation
Competing Interests:
Russian Federation
Aleksey Alekseyevich Tappakhov
58, Belinskogo St., Yakutsk 677000
Competing Interests:
There are no conflicts of interest
T. Ya. Nikolaeva
M.K. Ammosov North-Eastern Federal University
Russian Federation
Competing Interests:
Russian Federation
58, Belinskogo St., Yakutsk 677000
Competing Interests:
There are no conflicts of interest
N. Yu. Gorokhova
Republican Hospital No. 1 – M.E. Nikolaev National Center of Medicine
Russian Federation
Competing Interests:
Russian Federation
4, Sergelyakhskoye Sh., Yakutsk 677010
Competing Interests:
There are no conflicts of interest
L. T. Okoneshnikova
Republican Hospital No. 1 – M.E. Nikolaev National Center of Medicine
Russian Federation
Competing Interests:
Russian Federation
4, Sergelyakhskoye Sh., Yakutsk 677010
Competing Interests:
There are no conflicts of interest
A. N. Ylakhova
Republican Hospital No. 1 – M.E. Nikolaev National Center of Medicine
Russian Federation
Competing Interests:
Russian Federation
4, Sergelyakhskoye Sh., Yakutsk 677010
Competing Interests:
There are no conflicts of interest
E. E. Konnikova
M.K. Ammosov North-Eastern Federal University
Russian Federation
Competing Interests:
Russian Federation
58, Belinskogo St., Yakutsk 677000
Competing Interests:
There are no conflicts of interest
References
1. Haki M, Al-Biati HA, Al-Tameemi ZS, et al. Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment. Medicine (Baltimore). 2024 Feb 23;103(8):e37297. doi: 10.1097/MD.0000000000037297
2. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A Review. JAMA. 2021 Feb 23;325(8):765-79. doi: 10.1001/jama.2020.26858. Erratum in: JAMA. 2021 Jun 1;325(21):2211. doi: 10.1001/jama.2021.7928
3. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler. 2020 Dec;26(14):1816-21. doi: 10.1177/1352458520970841. Epub 2020 Nov 11.
4. Boyko A, Melnikov M. Prevalence and Incidence of Multiple Sclerosis in Russian Federation: 30 Years of Studies. Brain Sci. 2020 May 18;10(5):305. doi: 10.3390/brainsci10050305
5. Ward M, Goldman MD. Epidemiology and Pathophysiology of Multiple Sclerosis. Continuum (Minneap Minn). 2022 Aug 1;28(4):988-1005. doi: 10.1212/CON.0000000000001136
6. Antonazzo IC, Raschi E, Vignatelli L, et al. Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping. Drug Saf. 2017 Sep;40(9):823-34. doi: 10.1007/s40264-017-0551-0
7. Lysandropoulos AP, Du Pasquier RA. Demyelination as a complication of new immunomodulatory treatments. Curr Opin Neurol. 2010 Jun;23(3):226-33. doi: 10.1097/WCO.0b013e3283398c96
8. Bosch X, Saiz A, Ramos-Casals M; BIOGEAS Study Group. Monoclonal antibody therapy-associated neurological disorders. Nat Rev Neurol. 2011 Mar;7(3):165-72. doi: 10.1038/nrneurol.2011.1. Epub 2011 Jan 25.
9. Probert L. TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. Neuroscience. 2015 Aug 27;302:2-22. doi: 10.1016/j.neuroscience.2015.06.038. Epub 2015 Jun 24.
10. Smagina IV, Yelchaninova SA, Palashchenko AS, et al. Pathological and protective effects of tumor necrosis factoralpha in multiple sclerosis. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(10-2):14-20. doi: 10.17116/jnevro201911910214 (In Russ.)].
11. Kalliolias GD, Ivashkiv LB. TNF biology,pathogenic mechanisms and emerging therapeutic strategies. Nat Rev Rheumatol. 2016 Jan;12(1):49-62. doi: 10.1038/nrrheum.2015.169. Epub 2015 Dec 10.
12. Vulliemoz M, Brand S, Juillerat P, et al; on behalf of Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update. Digestion. 2020;101 Suppl 1:16-26. doi: 10.1159/000506898. Epub 2020 Jul 31.
13. Danve A, Deodhar A. Treatment of axialspondyloarthritis: an update. Nat Rev Rheumatol. 2022 Apr;18(4):205-16. doi: 10.1038/s41584-022-00761-z. Epub 2022 Mar 10.
14. Kemanetzoglou E, Andreadou E. CNS Demyelination with TNF-α Blockers. Curr Neurol Neurosci Rep. 2017 Apr;17(4):36. doi: 10.1007/s11910-017-0742-1
15. Rojas-Carabali W, Boada-Robayo L,Chacon-Zambrano D, et al. Multiple Sclerosis in a Patient with Intermediate Uveitis and Juvenile Idiopathic Arthritis Treated with Adalimumab: A Case Report. Ocul Immunol Inflamm. 2023 Nov;31(9):1873-6. doi: 10.1080/09273948.2022.2113800. Epub 2022 Sep 23.
16. Bensouda-Grimaldi L, Mulleman D, Valat JP, Autret-Leca E. Adalimumab-associated multiple sclerosis. J Rheumatol. 2007 Jan;34(1):239-40; discussion 240.
17. Tan H, Zhou L, Zhao C, et al. Multiplesclerosis associated with adalimumab use in ankylosing spondylitis. Neurol Sci. 2024 Aug;45(8):4055-8. doi: 10.1007/s10072-02407514-8. Epub 2024 Apr 10.
18. Matsumoto T, Nakamura I, Miura A, et al.New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review. Clin Rheumatol. 2013 Feb;32(2):271-5. doi: 10.1007/s10067-012-2113-2. Epub 2012 Nov 14.
19. Khosravi S, Zamani B, Motamed MR,Akhoundi FH. Adalimumab-induced CNS demyelination in a patient with multiple pre-existing autoimmune diseases: Treatment contemplation. Mod Rheumatol Case Rep. 2025 Jan 16;9(1):75-8. doi: 10.1093/mrcr/rxae069
20. Chighizola CB, Ferrito M, Marelli L, et al.Juvenile Idiopathic Arthritis, Uveitis and Multiple Sclerosis: Description of Two Patients and Literature Review. Biomedicines. 2022 Aug 21;10(8):2041. doi: 10.3390/biomedicines10082041
21. Sökmen O, Göcmen R, Tuncer A. Multiple Sclerosis – Like Demyelinating Lesions During Adalimumab Treatment in a Case with Crohn's Disease. Noro Psikiyatr Ars. 2022 Feb 21;59(4):342-4. doi: 10.29399/npa.27973
22. Uygunoglu U, Uluduz D, Tascilar K, Saip S. Multiple sclerosis during adalimumab treatment in a case with ankylosing spondylitis. Rheumatol Int. 2014 Jan;34(1):141-3. doi: 10.1007/s00296-012-2625-8. Epub 2012 Dec 27.
23. Hare NC, Hunt DP, Venugopal K, et al.Multiple sclerosis in the context of TNF blockade and inflammatory bowel disease. QJM. 2014 Jan;107(1):51-5. doi: 10.1093/qjmed/hcr237. Epub 2012 Jan 12
24. Shirah B, Altwirgi S, Faridoon I, Alghamdi S. Adalimumab-induced central nervous system demyelination in a patient with rheumatoid arthritis. Neuroradiol J. 2024 Apr;37(2):234-6. doi: 10.1177/19714009231173102. Epub 2023 Apr 26.
25. Alnasser Alsukhni R, Jriekh Z, Aboras Y. Adalimumab Induced or Provoked MS in Patient with Autoimmune Uveitis: A Case Report and Review of the Literature. Case Rep Med. 2016;2016:1423131. doi: 10.1155/2016/1423131. Epub 2016 Oct 20.
26. Engel S, Luessi F, Mueller A, et al. PPMSonset upon adalimumab treatment extends the spectrum of anti-TNF-α therapy-associated demyelinating disorders. Ther Adv Neurol Disord. 2020 Jan 2;13:1756286419895155. doi: 10.1177/1756286419895155
27. Thalayasingam N, Isaacs JD. Anti-TNFtherapy. Best Pract Res Clin Rheumatol. 2011 Aug;25(4):549-67. doi: 10.1016/j.berh.2011.10.004
28. Van Oosten BW, Barkhof F, Truyen L, et al.Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 1996 Dec;47(6):1531-4. doi: 10.1212/wnl.47.6.1531
29. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1999 Aug 11;53(3):457-65.
30. Skurkovich S, Boiko A, Beliaeva I, et al.Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. Mult Scler. 2001 Oct;7(5):277-84. doi: 10.1177/135245850100700502
31. Brambilla R, Ashbaugh JJ, Magliozzi R, et al. Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. Brain. 2011 Sep;134(Pt 9):2736-54. doi: 10.1093/brain/awr199
32. Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013 Aug;84(8):909-14. doi: 10.1136/jnnp-2012-304695. Epub 2013 Feb 21.
Review
For citations:
Tappakhov AA, Nikolaeva TY, Gorokhova NY, Okoneshnikova LT, Ylakhova AN, Konnikova EE. Multiple sclerosis associated with adalimumab: a case report and systematic review. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2025;17(3):70-76. (In Russ.) https://doi.org/10.14412/2074-2711-2025-3-70-76
Views:
66
Email this article 